| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca32fd2a44fd326ffd027a75a57bd13f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15071 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 |
| filingDate |
2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f2b2e288d086c997682c8a8f49f3adf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_470464a0cdf6234925298423abe1f49e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75183971b27c6c16f3a41b325bcbb4cf |
| publicationDate |
2009-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2047861-A1 |
| titleOfInvention |
Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications |
| abstract |
The invention relates to a combination of compounds for sequential administration to a mammalian host, to elicit a protective specific cellular immune response against infection by an Immunodeficiency Virus, comprising at least : n(iv) lentiviral vector particle, pseudotyped with a first determined heterologous viral envelope protein or viral envelope proteins; n(v) lentiviral vector particle, pseudotyped with a second determined heterologous viral envelope protein or viral envelope proteins different from said first determined envelope protein or envelope proteins; n nwherein said lentiviral vector particle of (i) and (ii) comprises in its genome a recombinant polynucleotide encoding one or several polypeptides comprising at least one antigen derived from a GAG antigen of an Immunodeficiency Virus and; nwherein said first and second viral envelope protein(s) do not sero-neutralize with each other and are suitable for in vivo transduction of mammalian cells. n It relates also to the use of the kit for prime-boost administration to a host in need thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109536464-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EA-024077-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10563254-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11447821-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014016383-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2427577-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10036039-B2 |
| priorityDate |
2007-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |